Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemiaElias Jabbour, Hagop M. Kantarjian, Xuelin Huang et al.|Cancer|2021Cited by 38
Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II StudyNicholas J. Short, Elias Jabbour, Hagop M. Kantarjian et al.|Blood|2020Cited by 20